Participate

madisonisabel.leggatt@uhn.ca

The Exercise Oncology Lab at the University of Toronto, led by Dr. Linda Trinh, is offering an exciting research study opportunity for adult cancer survivors. This study aims to test a supervised exercise program, combined with either exercise or behavioural counselling, to help participants increase their physical activity levels. The study is all done virtually in the comfort of their own homes and no in-person study visits are required.?

If you have any questions, please don’t hesitate to contact the research team at 416-946-5856 or via email at exercise.oncology@utoronto.ca.

Researchers at Nova Scotia Health are conducting a study to support breast and colorectal cancer patients’ and survivors’ experiences with follow-up care. Follow-up care is the care you receive after finishing cancer treatment to look for recurrences or new cancers, and to address your ongoing needs and concerns. These may be physical needs such as ongoing fatigue, pain, or nerve problems, or emotional needs such as fear of recurrence or depression. Previous research in this area has concluded that there are a number of problems with how follow-up care is currently being provided and there is an urgent need to improve the delivery of follow-up care to ensure that patients’ needs are being met. We know there is no-one-size fits all approach to delivering care and we need different care approaches to care that are matched to a person’s needs after treatment. Therefore, utilizing results from previous investigations, we designed a virtual self-management follow-up care application.

The supported self-management application is a mobile app designed to help cancer survivors navigate follow-up care and streamline access to resources alongside their usual care. The application will be used as an information hub and self-management tool alongside usual care, to address the physical, psychosocial, and practical needs of breast and colorectal cancer survivors.

The purpose of this study is to test the feasibility of implementing the virtual intervention at two cancer centers in Atlantic Canada and gather feedback regarding the intervention from cancer survivors and health care providers.

You are eligible to participate in this study if:
• live in Nova Scotia or New Brunswick
• are at least 18 years of age in Nova Scotia or 19 years of age in New Brunswick
• have been previously diagnosed with stage I-III breast or colorectal cancer and
• have completed primary treatment for your cancer (surgery and/or adjuvant systemic or radiation therapy) 6 months – 5 years ago

Participation in this study is voluntary and would involve access to the virtual application for six months. Participants will be prompted to complete a 15-minute questionnaire on the application before, once during,
and after access to the intervention. Select participants may be invited to partake in a one-time interview carried out using video-conferencing technology. The interview will be approximately 45 minutes in length,
and participants will be asked questions about their experience using the application and their opinion on its potential implementation. The Research Assistant will work with you to arrange a date and time for the
interview and will provide you with information needed to attend the video conference session. All interviews will be video, and audio recorded.

Before providing access to the application, the research team member will discuss the study with you, respond to any questions or concerns you may have, and confirm that you are still interested in participating.
If you have questions about this study or would like to participate, please contact:
Caroline Hovey
Email: cr344200@dal.ca

Did you or a loved one (adult) have to leave your community for cancer treatment in the past five years? Share your experience!

The Leukemia & Lymphoma Society of Canada (LLSC), in partnership with Save Your Skin Foundation and Quebec Cancer Coalition, is inviting people across Canada to take part in a national survey: Leaving Your Community for Cancer Treatment: Understanding the Impact

This survey explores the real-world impact of travelling for cancer treatment, whether for a day trip or a longer stay, including effects on finances, work, housing, education, family life, and social support.

Your experience can help highlight gaps in access to care and inform discussions with decision-makers across Canada.

Hello,

Researchers at the University of Calgary are conducting a study to understand how patient and physician factors – like their background, experiences, and personal beliefs – affect the way they make treatment decisions together. We also want to understand how these decisions impact patient’s health. We are currently seeking research participants for this study. Participation in this study is completely voluntary and you are free to change your mind at any time.

Who is eligible?

If you are over 18 years old, living in Alberta, have received a cancer diagnosis within the past two years, and been referred to a medical oncologist for a chemotherapy assessment, you may be eligible for this research study.

What will you be asked to do?

You will be asked to:

• Complete 2 questionnaires about your socio-demographic and psychosocial factors, as well as a few questions related to your cancer diagnosis
• Attend and actively participate in one focus group (approximately 90 minutes)

The focus groups will be conducted over Zoom software and will be video-recorded in order to be transcribed. The file will be labeled with the date of the focus group. You can choose whether to turn your camera on during the focus group. If you choose to turn your camera on, you will be identifiable in the video file. These videos will be transcribed and will only be accessed on study team password protected computers. Video recordings will be destroyed following transcription and transcripts will stored on the secure University of Calgary server (Sharepoint). Five years after the study is completed, all remaining files will be destroyed by an Alberta Health Services approved third-party destruction service provider.

What are the benefits of participating in this study?

Your information may influence the design and implementation of more effective strategies to improve communication between physicians and patients during treatment decision-making. You will also receive a $25 gift card for participating.

If you would like more information about the study or are interested in participating in this study, please contact:

Dr. Colleen Cuthbert, NP, PhD

Phone: 403-220-6198

Email: cacuthbe@ucalgary.ca

This study has received ethical approval through the Health Research Ethics Board of Alberta, HREBA.CC-25-0065

Looking to share your experience and contribute to research? The UBC Men’s Health Research Program is seeking men 45+ who have undergone a prostatectomy within the past 24 months to participate in a study exploring post-prostatectomy experiences. If you’re currently partnered, can communicate in English, and live in Canada, you may be eligible to participate and receive an honorarium for your time. Your insights could help improve care and support other men navigating this journey. Visit menshealthresearch.ubc.ca or contact christy.chan@ubc.ca to learn more.

From Lymphoma Canada

If you are a patient with relapsed/refractory follicular lymphoma and have been treated with Mosunetuzumab (Lunsumio) or Tafasitamab (Minjuvi), you can help by completing our survey.

Lymphoma Canada is preparing 2 submissions for Canada’s Drug Agency (CDA). This survey provides us with the patient input required for the submission. CDA uses this information to help them make recommendations to the provinces and territories regarding funding for new cancer drugs.

The therapies that will soon be reviewed by the CDA are:

• Mosunetuzumab (Lunsumio) for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies.
• Tafasitamab (Minjuvi) in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).

You do not need to live in Canada to complete this survey. You can still participate in this survey if you are a Follicular Lymphoma patient who has not received this therapy.

BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.

It should only take between 15-20 minutes of your time.

Please share and help us spread the word.
Thank you for your support.

From Lymphoma Canada

If you were newly diagnosed with Hodgkin Lymphoma and have been treated with Brentuximab vedotin containing regimen (BrECADD), you can help by completing our survey.

Lymphoma Canada is preparing a submission for Canada’s Drug Agency (CDA). This survey provides us with the patient input required for the submission. CDA uses this information to help them make recommendations to the provinces and territories regarding funding for new cancer drugs.

The therapy that will soon be reviewed by the CDA is the Brentuximab vedotin containing regimen (BrECADD), which includes etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone, for newly diagnosed Hodgkin Lymphoma patients.

You do not need to live in Canada to complete this survey. You can still participate in this survey if you are a Hodgkin Lymphoma patient who has not received this therapy.

BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.

It should only take between 15-20 minutes of your time.

Please share and help us spread the word.

Thank you for your support.

We are recruiting 55 and 85-year-olds who can converse in English for a research study. The purpose of this study is to investigate Ontarians’ values, attitudes, and beliefs about lung cancer screening.

Participants will be compensated $20 for completing an interview in person (Hamilton, ON), by telephone or video call.

If you are interested in participating, please fill out the eligibility survey here: https://dfmgp.mcmaster.ca/surveys/?s=MXFWX8483DJ88RLW

We hope to learn what you think about the importance of lung cancer screening, who you think should be screened, and your perspectives on the benefits and harms of lung cancer screening. Your participation can help advance our thinking about lung cancer screening in order to make a potential future lung cancer screening program in Ontario fair, effective, and an efficient use of health care dollars.

This research study is part of a doctoral thesis by Manisha Pahwa, a Ph.D. student at McMaster University, and has been reviewed by the Hamilton Integrated Research Ethics Board (project #8310)”

Bladder Cancer Canada is looking for bladder cancer patients and caregivers to complete their to ensure they are supporting patients in the best way possible. (more…)

The Lung Health Foundation is committed to delivering a support service to Lung Cancer patients and caregivers that is current, relevant and meaningful. With that goal in mind, they have created a survey to gather input and insights from those with lived experience to increase our understanding of the lung cancer journey, including diagnosis, navigation of care and gaps in support. This survey will take a few minutes to complete.

~